Diagnostic point-of-care tests in resource-limited settings

The Lancet Infectious Diseases

Volumn 14, Issue 3, 2014, Pages 239-249

  Drain, Paul K ^a   Hyle, Emily P ^a   Noubary, Farzad ^a,b,c   Freedberg, Kenneth A ^a   Wilson, Douglas ^d   Bishai, William R ^e,f   Rodriguez, William ^g   Bassett, Ingrid V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

^d EDENDALE HOSPITAL   (South Africa)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^g Daktari Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC TESTS, ROUTINE; HEALTH RESOURCES; HUMANS; POINT-OF-CARE SYSTEMS;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEALTH CARE FACILITIES AND SERVICES; HUMAN; METRIC SYSTEM; POINT OF CARE TESTING; RESOURCE LIMITED SETTING; REVIEW;

EID: 84894312020     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70250-0     Document Type: Review

References (147)

1. Chin CD, Laksanasopin T, Cheung YK, et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med 2011, 17:1015-1019.
2. Uys PW, Warren R, van Helden PD, et al. Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol 2009, 47:1484-1490.
3. Mabey D, Peeling RW, Ustianowski A, Perkins MD Diagnostics for the developing world. Nat Rev Microbiol 2004, 2:231-240.
4. Peeling RW, Mabey D Point-of-care tests for diagnosing infections in the developing world. Clin Microbiol Infect 2010, 16:1062-1069.
5. Mabey D, Peeling RW, Perkins MD Rapid and simple point-of-care diagnostics for STIs. Sex Transm Infect 2001, 7:397-398.
6. Diagnostics for tuberculosis: global demand and market potential. Geneva WHO, (accessed Jan 14, 2013). http://apps.who.int/tdr/publications/tdr-research-publications/diagnostics-tuberculosis-global-demand/pdf/tbdi/pdf.
7. Urdea M, Penny LA, Olmsted SS, et al. Requirements for high impact diagnostics in the developing world. Nature 2006, 444(suppl 1):73-79.
8. Hay Burgess DC, Wasserman J, Dahl CA Global health diagnostics. Nature 2006, 144(suppl 1):1-2.
9. Global infectious disease surveillance and detection: assessing the challenges - finding solutions, workshop summary 2007, Institute of Medicine, Forum on Microbial ThreatsForum on Microbial Threats, National Academies Press, Washington DC, (accessed Jan 14, 2013). http://www.nap.edu/catalog/11996.html.
10. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006, 444(suppl 1):49-57.
11. Lim YW, Steinhoff M, Girosi F, et al. Reducing the global burden of acute lower respiratory infections in children: the contribution of new diagnostics. Nature 2006, 444(suppl 1):9-18.
12. Estimating the global health impact of improved diagnostic tools for the developing world. Research highlights RAND Corporation, (accessed Jan 14, 2013). http://www.rand.org/content/dam/rand/pubs/research_briefs/2007/RAND_RB9293.pdf.
13. Kost GJ Principles and practice of point-of-care testing 2002, Lippincott, Williams and Wilkins, Philadelphia.
14. Clark LC, Lyons C Electrode systems for continuous monitoring in cardiovascular surgery. Ann N Y Acad Sci 1962, 102:29-45.
15. A timeline of pregnancy testing National Institutes of Health, (accessed Jan 14, 2013). http://history.nih.gov/exhibits/thinblueline/timeline.html.
16. Woo J, McCabe JB, Chauncey D, Schug T, Henry JB The evaluation of a portable clinical analyzer in the emergency department. Am J Clin Pathol 1993, 100:599-605.
17. Erickson KA, Wilding P Evaluation of a novel point-of-care system, the i-STAT portable clinical analyzer. Clin Chem 1993, 39:283-287.
18. Zaninotto M, Mion MM, Di Serio F, Caputo M, Ottomano C, Plebani M PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med 2010, 48:1029-1034.
19. Kost GJ, Tran NK Point-of-care testing and cardiac biomarkers: the standard of care and vision for chest pain centers. Cardiol Clin 2005, 23:467-490.
20. Verdu JM, Comin-Colet J, Domingo M, et al. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol 2012, 65:613-619.
21. Phillips S, Wyndham L, Shaw J, Walker SF How accurately does the Reflotron dry-chemistry system measure plasma total cholesterol levels when used as a community-screening device. Med J Aust 1988, 149:122-125.
22. Diar HA, Nakwa FL, Thomas R, Libhaber EN, Velaphi S Evaluating the QuikRead C-reactive protein test as a point-of-care test. Paediatr Int Child Health 2012, 32:35-42.
23. Cals JW, Chappin FH, Hopstaken RM, et al. C-reactive protein point-of-care testing for lower respiratory tract infections: a qualitative evaluation of experiences by GPs. Fam Pract 2010, 27:212-218.
24. Wilson D, Mayeza L, Bartman P, et al. Evaluation of nurse-led diagnosis of smear-negative tuberculosis using point-of-care C-reactive protein measurement in HIV-positive patients. 41st World Union Conference on Lung Health, 2011. Berlin, Germany: Nov 11-15, 2010. 100700-15.
25. Elusiyan JB, Adeodu OO, Adejuyigbe EA Evaluating the validity of a bedside method of detecting hypoglycemia in children. Pediatr Emerg Care 2006, 22:488-490.
26. Schwartz KL, Monsur J, Hammad A, Bartoces MG, Neale AV Comparison of point of care and laboratory HbA1c analysis: a MetroNet study. J Am Board Fam Med 2009, 22:461-463.
27. Wood JR, Kaminski BM, Kollman C, et al. Accuracy and precision of the axis-shield afinion hemoglobin A1c measurement device. J Diabetes Sci Technol 2012, 6:380-386.
28. Pollock N, Rolland JP, Kumar S, et al. A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Trans Med 2012, 4:152.
29. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial. Lancet Infect Dis 2012, 379:1705-1711.
30. Wleloch M, Hillarp A, Strandberg K, Misson C, Svensson PJ Comparison and evaluation of a point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res 2009, 124:344-348.
31. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011, 378:1572-1579.
32. Faal M, Naidoo N, Glencross DK, Venter WDF, Osih R Providing immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immun Defic Syndr 2011, 58:54-59.
33. Kassler WJ, Haley C, Jones WK, Gerber AR, Kennedy EJ, George JR Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. J Clin Microbiol 1995, 33:2899-2902.
34. Inojosa WO, Augusto I, Bisoffi Z, et al. Diagnosing human African trypanosomiasis in Angola using a care agglutination test: observational study of active and passive case finding strategies. BMJ 2006, 332:1479.
35. Hislop J, Quayyum Z, Flett G, Boachie C, Fraser C, Mowatt G Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol Assess 2010, 14:1-97.
36. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011, 53:1019-1023.
37. Minak J, Kabir M, Mahmud I, et al. Evaluation of rapid antigen point-of-care tests for detection of giardia and cryptosporidium species in human fecal specimens. J Clin Microbiol 2012, 50:154-156.
38. Mills LA, Kagaayi J, Makigozi G, et al. Utility of a point-of-care malaria rapid diagnostic test for excluding malaria as the cause of fever among HIV-positive adults in rural Rakai, Uganda. Am J Trop Med Hyg 2010, 82:145-147.
39. Atlas SJ, McDermott SM, Mannone C, Barry MJ The role of point of care testing for patients with acute pharyngitis. J Gen Intern Med 2005, 20:759-761.
40. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012, 157:558-566.
41. Colley DG, Binder S, Campbell C, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop Med 2013, 88:426-432.
42. Mabey D, Peeling RW, Ballard R, et al. Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex Transm Infect 2006, 82(suppl 5):13-16.
43. Benzaken AS, Sabido M, Galban EG, et al. Field evaluation of the performance and testing costs of a rapid point-of-care test for syphilis in a red-light district of Manaus, Brazil. Sex Transm Infect 2008, 84:297-302.
44. Benzaken AS, Sabido M, Galban E, et al. Field performance of a rapid point-of-care diagnostic test for antenatal syphilis screening in the Amazon region, Brazil. Int J STD AIDS 2011, 22:15-18.
45. Hatamabadi HR, Abdalvand A, Safari S, et al. Tetanus Quick Stick as an applicable and cost-effective test in assessment of immunity status. Am J Emerg Med 2011, 29:717-720.
46. Serodiagnosis Foundation for Innovative New Diagnostics, (accessed Dec 4, 2013). http://www.finddiagnostics.org/programs/hat-ond/hat/serodiagnosis.html.
47. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med 2010, 363:1005-1015.
48. Lawn SD, Kerkoff AD, Vogt M, Wood M Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
49. Boelaert M, El Safi S, Hailu A, et al. Diagnostics tests for Kala-Azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KA-tex in East Africa and the Indian sub-continent. Trans R Soc Trop Med Hyg 2008, 102:32-40.
50. Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 2012, 55:1312-1319.
51. Tolonen U, Kallio M, Ryhanen J, et al. A handheld nerve conduction measuring device in carpal tunnel syndrome. Acta Neurol Scand 2007, 15:390-397.
52. Eichner SF, Timpe EM Urinary-based ovulation and pregnancy: point-of-care testing. Ann Pharmacother 2004, 38:325-331.
53. Tovar JM, Gums JG Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother 2004, 38:126-133.
54. Nichols JH Point of care testing. Clin Lab Med 2007, 27:893-908.
55. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 2012, 9:e1001306.
56. Point of care diagnostic testing world markets TriMark Publications, LLCLLC, (accessed Sept 10, 2013). http://www.trimarkpublications.com/product_images/samples/pocdiagnosticssample.pdf.
57. Niemz A, Ferguson TM, Boyle DS Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol 2011, 29:240-250.
58. Schito M, Peter TF, Cavanaugh S, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis 2012, 205(suppl 2):1-12.
59. Yager P, Domingo GJ, Gerdes J Point-of-care diagnostics for global health. Annu Rev Biomed Eng 2008, 10:107-144.
60. Reid A Bringing the lab to the patient: developing point-of-care diagnostics for resource limited settings 2012, American Academy of Microbiology, Washington DC.
61. Aledort JE, Ronald A, Rafael M, et al. Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature 2006, 444(suppl 1):59-72.
62. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics 2009, WHO, Stop TB Partnership's New Diagnostics Working GroupStop TB Partnership's New Diagnostics Working Group, World Health Organization, Geneva.
63. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375:1920-1937.
64. McNerney R, Daley P Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011, 9:204-213.
65. Boyle DS, Hawkins KR, Steele MS, Singhal M, Cheng X Emerging technologies for point-of-care CD4 T-lymphocyte counting. Trends Biotechnol 2012, 30:45-54.
66. Cobelens F, Van den Hof S, Pai M, et al. Which new diagnostics for tuberculosis, and when?. J Infect Dis 2012, 205(suppl 2):191-198.
67. Palamountain KM, Baker J, Cowan EP, et al. Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis 2012, 205(suppl 2):181-190.
68. Point of care testing toolkit College of American Pathologists, (accessed Jan 14, 2013). http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cntvwrPtlt%7BactionForm.contentReference%7D=committees%2Fpointofcare%2Fpoct_toolkit.html&_state=maximized&_pageLabel=cntvwr.
69. Price CP, St John A Point-of-care testing in primary care. Point-of-care testing 2004, 3-9. AACC Press, Washington DC. 2nd edn. C.P. Price, A. St John, J.M. Hicks (Eds.).
70. Sokhna C, Mediannikov O, Fenollar F, et al. Point-of-care laboratory of pathogen diagnosis in rural Senegal. PLoS Negl Trop Dis 2013, 7:e1999.
71. Peeling RW, Holmes KK, Mabey D, Ronald A Rapid tests for sexually transmitted infections (STIs): the way forward. Sex TransmInfect 2006, 82(suppl 5):1-6.
72. Kettler H, White K, Hawkes S Mapping the landscape of diagnostics for sexually transmitted infections 2004, World Health Organization and TDR, Geneva, Switzerland.
73. World Development Report: making services work for poor people 2004, World Bank, Oxford University Press, New York, NY.
74. HIV counseling and testing in publically funded sites: 1995 summary report 1997, United States Center for Disease Control and Prevention, US Department of Health and Human Services, CDC, Atlanta.
75. Approval of a new rapid test for HIV antibody. MMWR 2002, 51:1051-1052. United States Center for Disease Control and Prevention.
76. Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:373-380.
77. Malonza IM, Richardson BA, Kreiss JK, Bwayo JJ, Stewart GC The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. AIDS 2003, 17:113-118.
78. Pai NP, Tulsky JP, Cohan D, Colford JM, Reingold AL Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis. Trop Med Int Health 2007, 12:1-12.
79. Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, Mudzori J Evaluation of the Partec Flow cytometer against the BD FACSCalibur system for monitoring immune responses of Human Immunodeficiency Virus-infected patients in Zimbabwe. Clin Vaccine Immunol 2007, 14:293-298.
80. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinic in Zimbabwe. J Acquir Immune Defic Syndr 2010, 55:1-7.
81. Renault CA, Traore A, Machekano RN, Israelski DM Validation of microcapillary flow cytometry for community-based CD4+ T lymphocyte enumeration in remote Burkina Faso. Open AIDS J 2010, 4:171-175.
82. Diaw PA, Daneau G, Coly AA, et al. Multisite evaluation of a point-of-care instrument for CD4+ T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr 2011, 58:103-111.
83. Manabe YC, Wang Y, Ibireer A, Auerbach B, Castelnuovo B Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS One 2012, 7:e34319.
84. Glencross DK, Coetzee LM, Faal M, et al. Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 2012, 15:3.
85. Steingart KR, Sohn H, Schiller I, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1. CD009593.
86. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
87. McMorrow ML, Masanja MI, Kahigwa E, Abdulla SM, Kachur SP Quality assurance of rapid diagnostic tests for malaria in routine patient care in rural Tanzania. Am J Trop Med Hyg 2010, 82:151-155.
88. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004, 329:1212.
89. Reyburn H, Mwakasungula E, Chonya S, et al. Clinical assessment and treatment in paediatric wards in the north-east of the United Republic of Tanzania. Bull World Health Organ 2008, 86:132-139.
90. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011, 53:321-325.
91. Jafari Y, Peeling RW, Shivkumar S, et al. Are Treponema pallidum specific rapid and point-of-care tests for syphilis accurate enough for screening in resource limited settings? Evidence from a meta-analysis. PLoS One 2013, 8:e54695.
92. Ritchie GE, Kengne AP, Joshi R, et al. Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. Diabetes Care 2011, 34:44-49.
93. Larson B, Schnippel K, Ndibongo B, Long L, Fox MP, Rosen S How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima analyzer in South Africa. PLoS One 2012, 7:e35444.
94. Noubary F, Hughes MD Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected persons. Stat Med 2010, 29:1932-1946.
95. Peeling RW, Smith PG, Bossuyt PM A guide for diagnostic evaluations. Nat Rev Microbiol 2006, 4:2-6.
96. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 2006, 20:1655-1660.
97. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007, 11:1-196.
98. Li J, Fine JP Assessing the dependence of sensitivity and specificity on prevalence in meta-analysis. Biostatistics 2011, 12:710-722.
99. McGee S Simplifying likelihood ratios. J Gen Intern Med 2002, 17:646-649.
100. Grimes DA, Schulz KF Refining clinical diagnosis with likelihood ratios. Lancet 2005, 365:1500-1505.
101. Akobeng AK Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 2007, 96:487-491.
102. Puhan MA, Steurer J, Bachmann LM, ter Riet G A randomized trial of ways to describe test accuracy: the effect on physicians' post-test probability estimates. Ann Intern Med 2005, 143:184-189.
103. Leung CC, Lee SS Rapid HIV tests: from meta-analysis to field application. Lancet 2012, 12:356-357.
104. Bland JM, Altman DG Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 327:307-310.
105. Jani IV, Sitoe NE, Chongo PL, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 2011, 25:807-812.
106. Scott LE, Galpin JS, Glencross DK Multiple method comparison: Statistical model using percentage similarity. Cytometry B Clin Cytom 2003, 54:46-53.
107. Stevens W, Gelman R, Glencross D, Scott L, Crowe S, Spira T Evaluation of CD4 enumeration technology for the monitoring of HIV disease. Nat Rev Microbiol 2008, 6:29-38.
108. Bland JM, Altman DG Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 2003, 22:85-93.
109. Lee SJ, Newton PN Use of the correlation coefficient to compare a point-of-care antigen test against a quantitative sandwich enzyme-linked immunosorbent assay for the detection of cryptococcal meningitis. Clin Infect Dis 2008, 55:1744-1745.
110. Lucas NP, Macaskill P, Irwig L, Bogduk N The development of a quality appraisal tool for studies of diagnostic reliability (QAREL). J Clin Epidemiol 2010, 63:854-861.
111. Lehe JD, Sitoe NE, Tobaiwa O, et al. Evaluating operational specifications of point-of-care diagnostic tests: a standardized scorecard. PLoS One 2012, 7:e47459.
112. Laurence C, Gialamas A, Yelland L, et al. A pragmatic cluster randomized controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in general practice setting: rationale, design and baseline characteristics. Trials 2008, 9:50.
113. Dowdy DW, Gounder CR, Corbett EL, et al. The ethics of testing a test: randomized trials of a health impact of diagnostic tests for infectious diseases. Clin Infect Dis 2012, 55:1522-1526.
114. Mosby's medical dictionary 2009, Mosby, Elsevier, Philadelphia, PA. 8th edn.
115. Ransohoff DF, Feinstein AR Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978, 299:926-930.
116. Replogle WH, Johnson WD, Hoover KW Using evidence to determine diagnostic test efficacy. Worldviews Evid Based Nurs 2009, 6:87-92.
117. Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa?. . . not everyone who should. AIDS 2010, 24(suppl 1):37-44.
118. Drummond MF, Sculper MJ, Torrnace GW, O'Brien BJ, Stoddart GL Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford.
119. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K Performance evaluation of the Alere PIMA™ CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr 2011, 58:141-147.
120. Ministry of Health, Zimbabwe. Summary and analysis of the evaluation of point-of-care CD4-testing to support anti-retroviral therapy for HIV-infected patients in Zimbabwe. April 3, 2011.
121. Evaluation report: Pima CD4 assay United States Centers for Disease Control and Prevention, (accessed Jan 14, 2013). http://www.biolinker.com.ar/productos/PDF_ALERE/Pima%20educ/Pima%20Evaluation%20Report%20CDC.pdf.
122. Baker CK, Mayes A, Smith J, et al. Evaluating the point-of-care Alere PIMA CD4 test with the traditional laboratory flow cytometer (accessed Jan 14, 2013). http://www.alere.co.uk/pdf/031111025702-Evaluating%20the%20POC%20Pima%20CD4%20test%20poster-%20Northampton%20%28lab%29.pdf.
123. Barnabas R, van Rooyen H, Joseph P, et al. Home point-of-care CD4 test provides accurate enumeration of CD4 count in South Africa. 19th conference on retroviruses and opportunistic infections; Seattle, WA, USA; March 5-8, 2012. 687.
124. Boardman AE, Greenberg DH, Vining AR, Weimer DL Cost-benefit analysis: concepts and practice 2006, Prentice Hall, Upper Saddle River. 3rd edn.
125. Craft D Practicing clinical microbiology in austere environments. Microbe 2010, 5:297-303.
126. Parsons LM, Somoskovi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011, 24:314-350.
127. Nsigaye R, Wringe A, Roura M, et al. From HIV diagnosis to treatment: evaluation of a referral system to promote and monitor access to antiretroviral therapy in rural Tanzania. J Int AIDS Soc 2009, 12:31.
128. Losina E, Bassett IV, Giddy J, et al. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One 2010, 5:8.
129. Larson BA, Brennan A, McNamara L, et al. Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Org 2010, 88:675-680.
130. Rosen S, Fox MP Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011, 8:e1001056.
131. Wilson D, Mbhele L, Badri M, et al. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis 2011, 15:919-924.
132. Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 2012, 55:1606-1698.
133. Lin SM, Wang TY, Liu WT, et al. Predictive factors for mortality among non-HIV-infected patients with pulmonary tuberculosis and respiratory failure. Int J Tuberc Lung Dis 2009, 13:335-340.
134. Jani IV The need for systematic evaluations of diagnostic tests. Clin Infect Dis 2010, 51:609-610.
135. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2010, 56:26-35.
136. Dowdy DW, O'Brien MA, Bishai D Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2008, 12:1021-1029.
137. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden counties: a cost-effectiveness analysis. PLoS Med 2011, 8:e1001120.
138. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based analysis. AIDS 2012, 26:987-995.
139. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012, 26:1663-1672.
140. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001, 344:824-831.
141. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005, 331:1431-1437.
142. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106-1110.
143. Hutson S To save lives, initiative pushes for standardized diagnostic tools. Nat Med 2010, 16:11.
144. Buchsbaum S. Working towards standards for global health point of care diagnostics. Next Generation Dx Summit; Washington DC, Aug 23-25, 2010.
145. Lijmer JG, Leeflang M, Bossuyt PMM Proposals for a phased evaluation of medical tests. MedDecis Making 2009, 29:13-21.
146. Mann G, Squire SB, Bissell K, et al. Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tooss. Int J Tuberc Lung Dis 2010, 14:1518-1524.
147. Lessells RJ, Cooke GS, Newell ML, et al. Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact. J Infect Dis 2011, 204(suppl 4):1187-1195.